V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20062699 | 20133830 | 1.65 | 53 | null | 2015-09-15 | 2015-09-29 | Doxorubicin 75mg/m2 | 02 | Y | TEMOZOLOMIDE | 100428795 |
| 20062872 | 20133831 | 1.65 | 83.6 | null | 2021-10-12 | 2021-11-10 | SCOPE 2 TRIAL | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101403551 |
| 20062881 | 20133832 | 0 | 0 | Palliative (P) | 2017-09-14 | 2017-09-22 | Cisplatin +FU +Trastuzumab - Load | Y | N | ARISTOTLE TRIAL | 101635047 |
| 20062931 | 20133833 | 1.69 | 65.7 | null | 2021-10-16 | 2022-03-14 | Rituximab | 2 | Y | CARBOPLATIN + PEMETREXED | 101010903 |
| 20063021 | 20133834 | 1.6 | 95 | null | 2018-02-12 | 2018-02-20 | FLUDARABINE + MELPHALAN | 02 | null | EOF | 100357790 |
| 20063028 | 20133835 | 1.53 | 64 | Neo-adjuvant (N) | 2017-10-23 | 2017-11-04 | ARISTOTLE TRIAL | 02 | null | SCOPE2 TRIAL | 100128107 |
| 20063247 | 20133836 | 1.75 | 60.4 | Neo-adjuvant (N) | null | 2020-01-31 | IVE | null | N | FLUOROURACIL + RT | 100648344 |
| 20063478 | 20133837 | 1.75 | 91.9 | Curative (C) | 2016-06-28 | 2016-07-28 | SCOPE 2 TRIAL | 02 | N | BORTEZOMIB + DARATUMUMAB + THALIDOMIDE | 100756910 |
| 20063511 | 20133838 | 1.54 | 96 | null | 2020-05-30 | 2020-06-14 | STS Rhabdomyosarcoma RMS 2005 VA | 02 | null | ATEZOLIZUMAB | 101451237 |
| 20063535 | 20133839 | 1.91 | 63.6 | null | 2020-08-31 | 2020-09-08 | FOXTROT TRIAL | 02 | null | CYTARABINE + DAUNORUBICIN | 101050887 |
| 20063629 | 20133840 | 1.79 | 89 | Palliative (P) | 2020-09-26 | 2020-10-04 | PHITT C SIOPEL-3HR | 02 | N | MELPHALAN | 101427593 |
| 20063709 | 20133841 | 0 | 0 | Palliative (P) | 2019-04-19 | 2019-04-19 | Topotecan (oral) | 02 | N | STAMPEDE TRIAL | 100147996 |
| 20063853 | 20133842 | 1.87 | 115.9 | null | 2015-06-17 | 2015-12-25 | Gemcitabine+Paclitaxel (Neo-tAnGo) | null | N | AZACITIDINE | 101153977 |
| 20063925 | 20133843 | 1.75 | 64.3 | Palliative (P) | 2020-10-02 | 2020-10-15 | CHOP R - 21 days | 02 | Y | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 101772865 |
| 20064134 | 20133845 | 1.82 | 80.1 | Curative (C) | 2019-03-28 | 2019-03-28 | CAM-PLEX Trial | 02 | N | CARBOPLATIN + PEMETREXED | 100233493 |
| 20064153 | 20133846 | 1.51 | 55.1 | Palliative (P) | 2018-08-04 | 2018-08-04 | EEF or EOF | 02 | null | BORTEZOMIB + CYCLOPHOSPHAMIDE | 100378089 |
| 20064203 | 20133847 | 1.69 | null | null | 2020-03-20 | 2020-03-21 | SCOPE 2 TRIAL | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100429173 |
| 20064306 | 20133848 | 1.65 | 118.2 | Palliative (P) | 2018-09-06 | 2018-09-15 | COSMIC TRIAL | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100222227 |
| 20064341 | 20133849 | 1.52 | 78 | null | 2017-01-09 | 2017-03-06 | POMALIDOMIDE | 02 | null | METHOTREXATE | 101664633 |
| 20064385 | 20133850 | 1.57 | 62.7 | Curative (C) | 2017-06-03 | 2017-06-17 | Lomustine | 02 | N | VINORELBINE | 101207198 |
| 20064427 | 20133851 | 1.6 | 91.6 | Palliative (P) | 2018-08-13 | 2018-08-13 | CABOZANTINIB | 02 | N | CAPECITABINE + STREPTOZOCIN | 101817598 |
| 20064498 | 20133852 | 1.8 | 62.5 | null | null | 2021-04-28 | DARATUMUMAB | null | N | CISPLATIN + FLUOROURACIL + RT | 101062441 |
| 20064608 | 20133853 | 1.55 | 76.1 | 03 | 2019-12-12 | 2019-12-20 | IBRUTINIB | 02 | N | GEMCITABINE + PACLITAXEL | 101795504 |
| 20064628 | 20133854 | 1.5 | 60 | null | 2021-05-11 | 2021-05-16 | Capecitabine + Streptozocin | 02 | null | BACILLUS CALMETTE-GUERIN | 100480368 |
| 20065092 | 20133855 | 1.84 | 84.4 | Adjuvant (A) | 2016-01-19 | 2016-01-28 | Cisplatin +FU +Trastuzumab - Maint | 02 | N | RADIUM 223 | 101785142 |
| 20065194 | 20133856 | 1.8 | 81.35 | Neo-adjuvant (N) | 2020-03-12 | 2020-04-03 | CISPLATIN + FLUOROURACIL + RT | 02 | N | CARBOPLATIN + EPIRUBICIN + FLUOROURACIL | 100836554 |
| 20065230 | 20133857 | 1.71 | 72 | Palliative (P) | 2020-09-03 | 2021-02-08 | Bevacizumab + Irinotecan + MdG | 02 | null | BACILLUS CALMETTE-GUERIN | 101587740 |
| 20065308 | 20133858 | 1.72 | 102 | Palliative (P) | 2019-12-04 | 2019-12-25 | Bevacizumab + FLUOROURACIL + IRINOTECAN | 02 | N | ACTICCA-1 TRIAL | 100424129 |
| 20065474 | 20133859 | 1.96 | 118.2 | 03 | 2018-08-06 | 2019-02-28 | OXALIPLATIN + MDG + PANITUMUMAB | 2 | N | STREPTOZOCIN + MDG | 100647715 |
| 20065554 | 20133860 | 1.83 | 83.2 | Palliative (P) | 2017-05-12 | 2017-05-30 | Etoposide + Ifosfamide (5 days) | 02 | N | GEFITINIB | 100051064 |
| 20065637 | 20133861 | 1.75 | 69.9 | null | 2019-08-01 | 2019-08-05 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | null | BEVACIZUMAB + IRINOTECAN + MdG | 100222094 |
| 20065801 | 20133862 | 1.57 | 66 | Palliative (P) | 2020-07-16 | 2020-08-12 | TRANSPLANT BEAM | N | N | BACILLUS CALMETTE-GUERIN | 101841107 |
| 20065823 | 20133863 | null | null | Palliative (P) | 2019-12-23 | 2019-12-23 | CISPLATIN + TEYSUNO | 02 | N | PALBOCICLIB | 100850182 |
| 20065871 | 20133864 | 1.19 | 66.2 | null | null | 2017-05-23 | Vinorelbine (oral) | null | null | CAV | 101707420 |
| 20065892 | 20133865 | 1.5 | 0 | Palliative (P) | 2016-10-07 | 2017-05-10 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | null | HEPATOBLASTOMA VHR BLOCK A CISPLATIN/DOX | 101497512 |
| 20065951 | 20133866 | 1.69 | 91 | 03 | 2018-07-18 | 2018-07-21 | Topotecan (oral) | 02 | N | AZACITIDINE + VENETOCLAX | 101644572 |
| 20065973 | 20133867 | 1.82 | 55 | null | 2016-08-28 | 2016-08-28 | BENDAMUSTINE + CYTARABINE + RITUXIMAB | 02 | N | BINIMETINIB + ENCORAFENIB | 101023012 |
| 20066065 | 20133868 | 1.65 | 80 | Adjuvant (A) | 2020-01-18 | 2020-02-24 | TCH (21 day Trastuzumab) Maint | 02 | N | BENDAMUSTINE + RITUXIMAB | 101436996 |
| 20066336 | 20133870 | 1.85 | null | Palliative (P) | 2019-08-31 | 2019-12-14 | TEMOZOLOMIDE | 02 | N | SCOPE2 TRIAL | 100683337 |
| 20066426 | 20133871 | 1.75 | 115.4 | Palliative (P) | 2021-08-01 | 2021-08-18 | VINORELBINE | 02 | N | ERLOTINIB | 101338415 |
| 20066495 | 20133872 | 1.6 | null | null | 2019-12-10 | 2019-12-24 | null | 02 | N | NIRAPARIB | 101230888 |
| 20066525 | 20133873 | 1.61 | 67.8 | Curative (C) | 2018-09-26 | 2018-10-03 | COSMIC TRIAL | 01 | N | BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB | 101677664 |
| 20066571 | 20133874 | 1.61 | 65.8 | null | 2021-08-28 | 2021-08-29 | Epirubicin (weekly) | 02 | null | BEVACIZUMAB + CAPECITABINE + OXALIPLATIN | 100904687 |
| 20066628 | 20133875 | 1.72 | 70 | Palliative (P) | 2018-08-23 | 2018-08-23 | CISPLATIN + TEYSUNO | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101383090 |
| 20066782 | 20133876 | 1.55 | 73 | Adjuvant (A) | 2018-06-30 | 2018-09-01 | CABOZANTINIB | 02 | N | CISPLATIN + CYCLOPHOSPHAMIDE + DOXORUBICIN | 100231068 |
| 20066853 | 20133877 | 1.83 | 79 | null | 2017-07-21 | 2017-12-28 | BRIGATINIB | 02 | null | STREPTOZOCIN + MDG | 100569725 |
| 20066854 | 20133878 | 1.82 | null | Palliative (P) | 2019-01-27 | 2019-02-04 | CHOP R - 21 days | N | null | INTERAACT TRIAL | 100535303 |
| 20067069 | 20133879 | 1.71 | 98.25 | Palliative (P) | 2019-02-03 | 2019-11-29 | EOF | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100962822 |
| 20067157 | 20133880 | 1.71 | 46 | Adjuvant (A) | 2018-08-03 | 2018-08-12 | EC | 02 | N | IRINOTECAN + MDG + PANITUMUMAB | 100656938 |
| 20067237 | 20133882 | 1.8 | 84.8 | null | 2020-01-06 | 2020-01-06 | HEP HR Hepatoblastoma gde carbo dox | 02 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 101838553 |